FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults

• UniQure N.V.'s (NASDAQ: QURE) partner CSL Limited (OTC: CSLLY) has received FDA approval for Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B.

• CSL licensed the exclusive global rights to Hemgenix from uniQure in May 2021.

• UniQure has received about $500 million so far from CSL and will also be eligible to get up to an additional $1.5 billion in commercial milestone payments and royalties.

• Cowen analyst Joseph Thome said that Hemgenix's price of $3.5 million is higher than the brokerage's estimated $1.9 million, but its consultants have been optimistic about the therapy's uptake, Reuters reported.

• Results from the pivotal HOPE-B trial support the FDA approval, the largest gene therapy trial in hemophilia B.

• Results from the study demonstrated that Hemgenix allowed patients to produce mean factor IX activity of 39% at six months and 36.7% at 24 months post-infusion.

• Seven to 18 months post-infusion, the mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by 54% compared to the six-month lead-in period on factor IX prophylactic replacement therapy (4.1 to 1.9).

• In addition, 94% of patients treated with Hemgenix discontinued prophylaxis and remained free of previous continuous routine prophylaxis therapy.

• The FDA has already cleared two gene therapies, Zynteglo and Skysona, from Bluebird bio Inc (NASDAQ: BLUE) in August and September, respectively.

• While Zynteglo was priced at $2.8 million, Skysona had a wholesale cost of $3.0 million.

• Price Action: QURE shares closed 1.74% higher at $23.40 during after-hours trading on Tuesday.

• Photo Via Company

See more from Benzinga

• Goldman Sachs Asset Management Unit Slapped With SEC Fine Over ESG Funds

• Mirati Therapeutics Garners Interest From Large Pharmas Ahead Of Much Awaited Data Next Month

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.